CYP cynata therapeutics limited

0.00%

16.5¢

I just realised that I left of the link to the statement as...

First 566 Last

Share
Profile

Follow
pfeifer1982

1,315 Posts.

3973

23/06/24

20:36

Post #: 74448900
Share

Originally posted by JB1975: ↑

After re-reading the announcements I saw that despite there not being a reference like EAP 276, patients appear to have been treated using the improved process right up to (including 2023): "Mesoblast presented consistently high survival in patients treated in RYONCIL, in children with SR-aGVHD in the EAP between 2008-2015, in the Phase 3 trial MSB-GVHD001 between 2015-2018, and in the Emergency Investigational New Drug (EIND) protocol from 2015-2023."

2015-2023 and therefore after GVHD-001/002, after CRL #1 and also after CRL #2.

----------Ok. Still reading. Which announcement did you get the quote from? If there was only a few I'd check without asking but there are quite a few it could be in in 2023 and 2024 referring to a "protocol from 2015-2023".

BTW. Bazsa is still asking about the 11 data points. Part of me wants to show him my sources because why not be nice the other part of me says you've told him several times already he never gets it, doesn't check sources and it would be a lot more efficient from a communication point of view to simply not reply to him and so reduce the chances of him reporting me because he takes issue with a tone of frustration or something.

On one hand I think with a very large amount of time I might be able to convince even Bazsa - but it will take a long time potentially as he'll explore ever possible way of misinterpreting what I say I suspect.

Are you clear how I got down to 11 data points? Can you remember my sources (serum samples from Kasikis et al (25), statement from Silviu at ODAC specifically mentions patients) - but if you aren't perhaps its worth me doing a refresher so others perhaps besides Bazsa can see I'm not pulling stuff out of my proverbial. Bazsa thinks 40 is reasonable - that's not unreasonable for him to think that its just ignorant because he hasn't integrated the sources I have to cut that number down from 40 in my opinion - and others won't have done that either.

Expand

I just realised that I left of the link to the statement as quoted:

"Mesoblast presented consistently high survival in patients treated in RYONCIL, in children with SR-aGVHD in the EAP between 2008-2015, in the Phase 3 trial MSB-GVHD001 between 2015-2018, and in the Emergency Investigational New Drug (EIND) protocol from 2015-2023."
https://investorsmedia.mesoblast.com/static-files/adfc1ba0-bd4d-47bd-b0a0-a0b3516b0520

Usually I provide the link with the quote, but must have forgotten this time.

CYP Price at posting: 27.0¢ Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

FTL

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

SGQ

St George banks $5M from placement to ramp up Araxá Rare Earths Project

RNU

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Most investors will get this earnings season wrong. Will you?

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

ASE

Astute delivers high-grade lithium hits at Red Mountain

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

First 566 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 16.5¢		Change 0.000(0.00%)		Mkt cap ! $37.28M

Open	High	Low	Value	Volume
17.0¢	17.0¢	16.0¢	$29.18K	176.1K

Buyers (Bids)

No.	Vol.	Price($)
2	66467	16.0¢

Sellers (Offers)

Price($)	Vol.	No.
17.5¢	65000	1

View Market Depth

No.	Vol.	Price($)
2	66467	0.160
4	181490	0.155
5	318045	0.150
4	81775	0.145
4	307863	0.140

Price($)	Vol.	No.
0.175	65000	1
0.185	35419	2
0.190	114978	3
0.195	5764	1
0.200	55400	2

Last trade - 15.59pm 25/07/2025 (20 minute delay)

CYP (ASX) Chart

I just realised that I left of the link to the statement as...

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Most investors will get this earnings season wrong. Will you?

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Astute delivers high-grade lithium hits at Red Mountain

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I just realised that I left of the link to the statement as...

Top Stories

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Most investors will get this earnings season wrong. Will you?

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Astute delivers high-grade lithium hits at Red Mountain

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News